| 000 | 01590 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250514005711.0 | ||
| 264 | 0 | _c20011204 | |
| 008 | 200112s 0 0 eng d | ||
| 022 | _a0920-1211 | ||
| 024 | 7 |
_a10.1016/s0920-1211(01)00287-x _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMarson, A G | |
| 245 | 0 | 0 |
_aLevetiracetam, oxcarbazepine, remacemide and zonisamide for drug resistant localization-related epilepsy: a systematic review. _h[electronic resource] |
| 260 |
_bEpilepsy research _cSep 2001 |
||
| 300 |
_a259-70 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Meta-Analysis; Systematic Review | ||
| 650 | 0 | 4 |
_aAcetamides _xtherapeutic use |
| 650 | 0 | 4 |
_aAnticonvulsants _xtherapeutic use |
| 650 | 0 | 4 |
_aCarbamazepine _xanalogs & derivatives |
| 650 | 0 | 4 |
_aControlled Clinical Trials as Topic _xstatistics & numerical data |
| 650 | 0 | 4 | _aDrug Resistance |
| 650 | 0 | 4 |
_aEpilepsies, Partial _xdrug therapy |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aIsoxazoles _xtherapeutic use |
| 650 | 0 | 4 | _aLevetiracetam |
| 650 | 0 | 4 | _aLinear Models |
| 650 | 0 | 4 | _aLogistic Models |
| 650 | 0 | 4 | _aOxcarbazepine |
| 650 | 0 | 4 |
_aPiracetam _xanalogs & derivatives |
| 650 | 0 | 4 | _aZonisamide |
| 700 | 1 | _aHutton, J L | |
| 700 | 1 | _aLeach, J P | |
| 700 | 1 | _aCastillo, S | |
| 700 | 1 | _aSchmidt, D | |
| 700 | 1 | _aWhite, S | |
| 700 | 1 | _aChaisewikul, R | |
| 700 | 1 | _aPrivitera, M | |
| 700 | 1 | _aChadwick, D W | |
| 773 | 0 |
_tEpilepsy research _gvol. 46 _gno. 3 _gp. 259-70 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/s0920-1211(01)00287-x _zAvailable from publisher's website |
| 999 |
_c11443050 _d11443050 |
||